Barinthus Biotherapeutics (NASDAQ:BRNS) Receives “Outperform” Rating from William Blair

William Blair reiterated their outperform rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report sent to investors on Thursday morning, RTT News reports.

Other analysts also recently issued reports about the company. Barclays decreased their price target on Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating on the stock in a research note on Thursday. HC Wainwright restated a buy rating and issued a $8.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday, June 7th.

Barinthus Biotherapeutics Trading Down 4.2 %

Shares of BRNS stock opened at $1.83 on Thursday. The business’s 50 day moving average is $2.35 and its two-hundred day moving average is $2.73. Barinthus Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $5.10. The company has a market capitalization of $71.42 million, a P/E ratio of -0.99 and a beta of -0.46.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Monday, May 13th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.24. As a group, equities analysts predict that Barinthus Biotherapeutics will post -2.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. BlueCrest Capital Management Ltd acquired a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 542,673 shares of the company’s stock, valued at approximately $1,292,000. BlueCrest Capital Management Ltd owned about 1.39% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.